LFMD Q2 2026 - Post-Call Earnings Update

Event: Quartr Q2 2026 event Retrieved: 2026-08-06T00:12:00Z Comparison mode: maximal Scorecard contract: v1

Consensus scorecard

Management and Q&A

Prepared remarks — Chairman and CEO Justin Schreiber:

• Opened by addressing the miss directly: revenue of $47.3 million was within the guidance range, but adjusted EBITDA was a loss of approximately $3.5 million, "reflecting elevated customer acquisition costs earlier in the quarter and a new $39 introductory offer." He said the company "missed our own target" and that the underestimated near-term profitability pressure "is a miss we own."
• Listed what changed in the quarter: a restructured customer acquisition model, a transformed leadership team, an advanced transition toward branded GLP-1 therapies and longer duration members, the launch of the Halozyme pharmaceutical collaboration, continued scaling of pharmacy, women's health, insurance, Medicare, enterprise and technology capabilities, and steps to reduce reliance on paid media.
• Framed the strategy as a deliberate rejection of the standard direct-to-consumer playbook — "chase the lowest priced medication, maximize promotional volume, concentrate spend on a single advertising channel, and optimize for immediate cash collection" — which he said produces shallow relationships, volatile acquisition economics, regulatory exposure and revenue that must constantly be replaced.
• Cited supporting evidence: recurring bill revenue at approximately 84% of total revenue, gross margin expanded to approximately 89%, and gross profit essentially flat despite lower year-over-year revenue.
• Confirmed the expense actions promised last quarter: advertising and marketing down approximately $1.8 million sequentially and general and administrative down approximately $1.5 million, with the benefit expected to be more visible in the second half.
• On acquisition mix: said "no durable healthcare platform should have to purchase substantially all of its growth at whatever price the media market sets," and that a larger share of demand should over time come from pharmaceutical manufacturers, employers, insurers, Medicare, national strategic partners, patient referrals and cross-care offerings. He was explicit that "Paid media will remain our largest acquisition channel in the near term."
• Said acquisition costs have moderated since mid-June, that Rex MD unit economics "are among the strongest we have seen in a long time," and that weight management customer acquisition costs are approximately 50% below their June peak.
• Weight management: said the quarter was highly competitive, that major competitors reduced introductory pricing, and that LifeMD responded by cutting the branded GLP-1 introductory price to $39 — a decision that "reduced upfront cash collection and contributed to the EBITDA shortfall." Before the change, approximately 25% of new weight management patients year to date selected multi-month packages; after the change, approximately 85% did.
• Said internal models "currently indicate that the return on advertising investment from these cohorts can exceed that of the prior higher upfront price offering, despite the lower first-month cash collection."
• On the compounded GLP-1 regulatory environment: "I have been candid that the regulatory environment for compounded GLP-1 medications evolved differently than I initially expected," while maintaining conviction in branded medicines, longitudinal care, insurance access and manufacturer relationships.
• Ended the quarter with approximately 108,000 weight management patients, deep integrations with LillyDirect and NovoCare, and infrastructure for oral formulations and next-generation medicines such as CagriSema and Retatrutide.
• Women's health: said the program "encountered some pressure during the quarter" but recent trends have improved, with new patient acquisitions up substantially over the last 30 days and acquisition costs down. The patient base grew 134% quarter over quarter and is expected to grow another 300%-400% by year-end. He said the program has "the potential to become as meaningful as weight management."
• XYOSTED: an exclusive telehealth co-marketing collaboration with Halozyme's wholly owned subsidiary Antares Pharma for the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The initial self-pay program launched in July across 37 states at an all-in price of $249 per month, with LifeMD's affiliated pharmacy as primary dispensing pharmacy. He said it "requires startup investment during 2026 and early 2027 before the initial cohorts mature" and could be "a meaningful contributor to both our top and bottom line in 2027," and described it as "a blueprint" with discussions underway with other manufacturers.
• Affiliated medical group: providers are licensed nationally and increasingly cross-trained across the portfolio; 47 new providers were hired to support anticipated second-half demand.
• Pharmacy: 50-state operation with gross margins of approximately 90%; scaling across branded direct-to-patient fulfillment, generics and personalized compounded therapies; more than 30 compounded products planned between now and year-end across hormone health, sleep, dermatology, sexual health and longevity. "Our objective is not to build a commodity mail order pharmacy."
• Insurance and Medicare: benefits infrastructure now reaches approximately 175 million covered lives; insurance penetration is approximately 10% of new patients on the primary care platform; a new Medicare Bridge Program helps Medicare beneficiaries access branded GLP-1 medications, with early demand encouraging but "too soon to draw broad conclusions."
• Named leadership additions: CFO Atul Kavthekar, new CTO Umesh Sripad, CMO Chris Pisano, and GM and SVP of Growth Tim Ragland.
• On the guidance revision: "Revising guidance is not an outcome we accept lightly, and we recognize that credibility is earned through execution," while arguing the full-year revision "should not obscure" a Q4 exit run rate of approximately $250 million of revenue and approximately $22 million of adjusted EBITDA excluding XYOSTED launch cost.
• Closed by saying the company expects "to return to adjusted EBITDA profitability in the third quarter and deliver substantial sequential improvement in the fourth quarter."

Prepared remarks — CFO Atul Kavthekar:

• Reminded listeners that all year-over-year comparisons are on a continuing operations basis excluding WorkSimpli, divested 4 November 2025.
• Revenue of $47.3 million was within the $47-$50 million guidance range and down approximately 6% sequentially, reflecting the planned step-down in marketing investment, increased cost per acquisition through much of the quarter, and the June weight management price change from $79 to $39 for the initial month "to stay in line with competitors."
• Revenue declined approximately 4% against prior-year telehealth revenue of $49 million, "reflecting the continued and deliberate mix shift from compounded to branded GLP-1 therapies."
• Active subscribers were 356,000 at quarter end; the sequential decline "reflects a deliberate shift in our weight management customer base away from the primarily month-to-month subscriber base to a higher retention and higher LTV multi-month subscriber base."
• Gross margin expanded to 89%, up approximately 60 basis points sequentially, on lower shipping and fulfillment costs, improved provider efficiency and continued scaling of the in-house pharmacy.
• Advertising and marketing expense of $28 million was "slightly above the range indicated on our prior call" but down $1.8 million sequentially; other general and administrative expenses fell approximately $1.5 million on lower employee and professional services expense; all other operating expenses fell approximately $700,000 sequentially.
• GAAP net loss from continuing operations attributable to common stockholders of $7.9 million, or $0.16 per share. Adjusted EBITDA loss of approximately $3.5 million, driven by elevated customer acquisition costs on comparable spend levels and the $39 introductory offer, with "the monthly trajectory improved consistently through the quarter."
• Ended the quarter with $25.1 million in cash; cash flow was pressured by marketing investment and the transition timing of the $39 offer. Expects cash to improve through year-end on stronger upfront collections from multi-month plans and lower second-half marketing, partially offset by working capital for increased pharmacy production. The credit agreement was amended at quarter end "on favorable terms."
• On the guidance reset: prior guidance assumed acquisition costs would be more predictable and that partnership agreements would launch earlier. "We recognize the timing is not in our sole control," so second-half guidance is based on "more concrete current trends and on arrangements with high visibility," and is presented after adjusting for LifeMD's share of expected XYOSTED launch costs.
• Quantified the XYOSTED investment at $2-$3 million in 2026, described it as "a true partnership with direct costs split between the two companies throughout the life of the program," and said initial patient cohorts are anticipated to become accretive to EBITDA in mid-2027.

Question and answer:

• David Larsen (BTIG) asked about peptides and the Washington discussions. Schreiber said the company has no revenue number to share but expects "a considerable amount of demand from current patients" if the FDA permits compounding, plus demand outside the platform. He said LifeMD is "working on a solution to essentially either acquire or convert our non-sterile pharmacy into a sterile pharmacy," has vendors that would manufacture in 503B pharmacies for fulfillment through its 503A, and plans "a conservative approach to the whole peptide space."
• On weight management subscriber mix and branded economics, Schreiber said relationships with Eli Lilly and Novo Nordisk are integrations only: "We don't receive any economics period from either of those companies," though he expects the relationships to evolve. He said almost 95% of new weight management patients are going on a branded therapy, with much of the remaining 5% likely receiving other medications, and that the compounding business "has just become very small" and "pretty insignificant to earnings moving forward." He said unit economics on branded GLP-1 show "very attractive returns over two or three years."
• Kavthekar added that the shift from month-to-month to multi-month subscribers is "a profound change in the unit" economics, not just for EBITDA but for cash, because "These multi-month subscribers wind up paying back in terms of cash in a very short period of time."
• Sarah James (Cantor Fitzgerald) asked what 2027 EBITDA margin could look like versus the roughly 10% exit rate, and which of XYOSTED, Medicare, employer partnerships or pharmacy scaling shows up first. Kavthekar said the core business will show first, that new products in the pipeline are not in this year's guidance and "are going to really shape our 2027 guidance," and that XYOSTED will be "mostly in growth and investment mode... probably for at least for a few quarters."
• On deepening patient relationships, Schreiber used women's health as the example: patients entering on hormone therapy who then discuss sexual wellness and testosterone, use the weight loss and GLP-1 support offering, take in-home labs routed to Quest Diagnostics and LabCorp, and access early-stage cardiology and psychiatry offerings. Kavthekar added a bone health program planned for later this year and described connecting program data with patient medical data through a Health Information Exchange connection plus lab data.
• Steve Dechert (KeyBanc) asked about insurance usage. Schreiber said approximately 10% of new patients now come in through an insurance flow, "much smaller than that" a quarter or two ago, and that demand is stronger for insurance covering medications than consults because consult pricing "is not prohibitively expensive." He declined to give a target.
• Katie (for Yi Chen, H.C. Wainwright) asked for women's health subscriber and revenue detail. Schreiber declined to give patient numbers, said the prior guidance of approaching a $5 million quarterly revenue run rate by Q4 "might be a little bit aggressive," and revised it to "somewhere between a $3 million and $5 million quarterly revenue run rate by Q4 of this year." He said recent new patient acquisitions have hit 50-100 per day on several days and that the goal is several hundred per day.

Guidance and KPI clarification

Updated neutral analysis

• The call did not change the quarter's scorecard: revenue of $47.3 million missed consensus by 3.8% and GAAP diluted EPS from continuing operations of $(0.16) missed by 9.8%. The call adds that revenue landed inside the company's own $47-$50 million range while adjusted EBITDA of approximately $(3.5) million missed the company's internal target — a distinction management drew explicitly and repeatedly.
• Management gave an unusually direct account of the shortfall: elevated customer acquisition costs early in the quarter plus a deliberate cut in the branded GLP-1 introductory price from $79 to $39 that reduced upfront cash collection. Schreiber said "we missed our own target" and "that's a miss we own."
• The $39 price change is the most consequential disclosure. It shifted the mix of new weight management patients selecting multi-month packages from approximately 25% to approximately 85% — a structural change in cash timing and, per management, lifetime value. Management asserts the multi-month cohorts can produce a higher return on advertising investment than the prior higher-priced offering, but that is an internal model, not a reported result.
• The guidance cut is substantial and management framed it as timing rather than trajectory. Full-year revenue is now $205.5-$212.5 million and full-year adjusted EBITDA $(6) million to breakeven. Kavthekar attributed the reset to prior guidance having assumed more predictable acquisition costs and earlier partnership launches, and said second-half guidance now rests only on "more concrete current trends and on arrangements with high visibility."
• The second-half ramp is steep and back-end loaded. Q3 revenue is guided to $48-$51 million against $47.3 million delivered, then Q4 to $60-$64 million — a sequential increase of roughly 25% at the midpoints in a single quarter, with adjusted EBITDA moving from a $(3.5) million loss to $3-$6 million of profit across two quarters.
• Management's preferred framing — a Q4 exit run rate of approximately $250 million of revenue and approximately $22 million of adjusted EBITDA — is stated at the Q4 midpoint and excludes XYOSTED launch cost, so it is an adjusted annualization of a single guided quarter rather than a reported result.
• The compounding business, previously a material revenue source, has effectively ended: almost 95% of new weight management patients are on branded therapy and management called compounding "pretty insignificant to earnings moving forward." Schreiber conceded the compounded GLP-1 regulatory environment "evolved differently than I initially expected."
• Manufacturer relationships remain non-economic. Schreiber confirmed LifeMD receives no economics from Eli Lilly or Novo Nordisk, only integrations, while expecting that to evolve. The one contracted manufacturer relationship, XYOSTED with Antares Pharma, requires $2-$3 million of LifeMD investment in 2026 and does not turn accretive until mid-2027.
• The mix and margin evidence management cites is real: gross margin expanded to approximately 89% with gross profit essentially flat on lower revenue, recurring bill revenue is approximately 84% of total, and pharmacy carries approximately 90% gross margins. The question the call leaves open is whether declining absolute revenue can be reversed without the paid media spend the company is deliberately reducing.
• Subscriber count fell to 356,000. Management attributes this to the deliberate move away from month-to-month subscribers and did not state the prior-quarter figure, so the size of the decline is not determinable from the call.
• Women's health guidance was reduced within the call itself: Schreiber said the prior "approaching $5 million" Q4 quarterly run rate "might be a little bit aggressive" and revised it to $3-$5 million, while simultaneously guiding the patient base to grow 300%-400% by year-end.
• Liquidity is a live constraint. Cash of $25.1 million against a guided full-year adjusted EBITDA of $(6) million to breakeven, continued marketing spend, XYOSTED investment, and working capital for pharmacy production. Management expects cash to improve through year-end and noted the credit agreement was amended on favorable terms, without disclosing the terms.
• The peptide opportunity discussed at length in Q&A is contingent on an FDA action that has not occurred, requires LifeMD to acquire or convert a sterile pharmacy it does not currently have, and was explicitly declined a revenue estimate.

Market context and limitations

• API Ninjas snapshot: LFMD $3.68 on NASDAQ, volume 1,772,327, quote timestamped 2026-08-05T22:41:24Z, retrieved 2026-08-06T00:12:00Z. The release published after the U.S. close on 2026-08-05 and the call was held that afternoon; this is a single quote of unstated session basis captured after the close, not a measured reaction to either the release or the call.
• The consensus scorecard is carried forward unchanged from the preliminary report for this event (reports/preliminary/2026-08-05-lfmd-q2-2026.md). No new actual in the call changes it: management stated revenue of $47.3 million and a GAAP loss from continuing operations of $0.16 per share, consistent with the $47.281 million and $(0.16) in the release.
• Every figure above comes from the Quartr transcript for event 661684, which is complete and not live. The full transcript was read.
• Figures management stated on the call are reproduced at the precision used on the call, which is generally rounded to one decimal place and therefore differs slightly from the release's exact figures.
• Adjusted EBITDA is a non-GAAP measure the company defines as income or loss attributable to common stockholders before items outlined in the release; it is reconciled in the release rather than on the call.
• All year-over-year comparisons are on a continuing operations basis excluding WorkSimpli, divested 4 November 2025, as management stated.
• Prior-quarter gross margin of approximately 88.4% and prior-quarter advertising and marketing expense of $29.8 million are implied from the stated current values and the stated sequential changes; management did not state them on the call.
• Other general and administrative expense and all other operating expenses were disclosed only as sequential changes, not absolute amounts.
• Prior FY2026 guidance ranges were not restated on the call, so the size of the revenue and adjusted EBITDA cuts cannot be quantified from this transcript.
• The prior-quarter active subscriber count and the prior-quarter weight management patient count were not stated, so the sequential declines are not quantified.
• The approximately $250 million revenue and approximately $22 million adjusted EBITDA run-rate figures are management annualizations of the Q4 guidance midpoint excluding XYOSTED launch cost; they are not guidance and not a reported result.
• Management's statement that multi-month cohorts can produce a higher return on advertising investment than the prior offering is described as an internal model output and was not quantified.
• Women's health revenue, patient counts and subscriber figures were explicitly declined; only the growth percentages and the revised $3-$5 million Q4 run-rate range were given.
• The terms of the amended credit agreement were not disclosed.
• The peptide discussion concerns a potential FDA action that has not occurred; management declined to provide any revenue estimate and the sterile pharmacy capability required is described as being worked on, not in place.
• The investor presentation posted with the release and the Form 10-Q filed the same day were not read for this update.

Source links

• Quartr Q2 2026 event overview
• Quartr Q2 2026 earnings call transcript
• Quartr Q2 2026 earnings release
• Preliminary report for this event